Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -3.28% is 46% above its 5-year average of -6.03%, near the high end of its 5-year range (-19.10%–2.32%).
60.78% below its 12-month average of -2.04%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 2.32%.
EBITDA MARGIN
-3.28%
EBITDA MARGIN AVG TTM
-2.04%
EBITDA MARGIN AVG 3Y
-5.03%
EBITDA MARGIN AVG 5Y
-6.03%
EBITDA MARGIN AVG 10Y
-7.89%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-60.78%
CURRENT VS 3Y AVG
+34.79%
CURRENT VS 5Y AVG
+45.56%
CURRENT VS 10Y AVG
+58.43%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
OrthoPediatrics Corp.
Market Cap
$580.22M
EBITDA Margin
-3.28%
TTM Avg
-2.04%
3Y Avg
-5.03%
5Y Avg
-6.03%
Market Cap
$563.97M
EBITDA Margin
-155.10%
TTM Avg
-103.66%
3Y Avg
-79.43%
5Y Avg
-77.63%
Market Cap
$596.72M
EBITDA Margin
40.74%
TTM Avg
33.91%
3Y Avg
-21.02%
5Y Avg
1.67%
Market Cap
$562.50M
EBITDA Margin
52.98%
TTM Avg
1.13%
3Y Avg
-15499.35%
5Y Avg
-14628.26%
Market Cap
$605.22M
EBITDA Margin
-20.76%
TTM Avg
-19.02%
3Y Avg
-15.62%
5Y Avg
12.71%
Market Cap
$552.54M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$551.88M
EBITDA Margin
-27.54%
TTM Avg
-4.08%
3Y Avg
-49.61%
5Y Avg
-102.69%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OrthoPediatrics Corp. (KIDS) | $580.22M | -3.28% | -2.04% | -5.03% | -6.03% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $569.15M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $563.97M | -155.10% | -103.66% | -79.43% | -77.63% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $596.72M | 40.74% | 33.91% | -21.02% | 1.67% |
| CorMedix Inc. (CRMD)vs › | $562.50M | 52.98% | 1.13% | -15499.35% | -14628.26% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $605.22M | -20.76% | -19.02% | -15.62% | 12.71% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $552.54M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $551.88M | -27.54% | -4.08% | -49.61% | -102.69% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $549.58M | -970.11% | -861.99% | -583.02% | -735.09% |
Gross Margin
73.7%
EBITDA Margin
-3.3%
Operating Margin
-9.0%
Net Margin
-15.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 2.32% |
| 2026-03-31 | -4.40% |
| 2025-12-31 | 0.16% |
| 2025-09-30 | 0.71% |
| 2025-06-30 | -8.98% |
| 2025-03-31 | -11.32% |
| 2024-12-31 | -19.10% |
| 2024-09-30 | -0.52% |
| 2024-06-30 | -1.68% |
| 2024-03-31 | -10.51% |
| 2023-12-31 | -7.65% |
| 2023-09-30 | -0.60% |
| 2023-06-30 | -3.81% |
| 2023-03-31 | -15.02% |
| 2022-12-31 | -14.41% |
| 2022-09-30 | -0.19% |
| 2022-06-30 | -1.25% |
| 2022-03-31 | -14.63% |
| 2021-12-31 | -11.09% |
| 2021-09-30 | -3.67% |
| 2021-06-30 | -0.89% |
| 2021-03-31 | -16.00% |
| 2020-12-31 | -55.11% |
| 2020-09-30 | -0.39% |
| 2020-06-30 | -37.57% |
| 2020-03-31 | -19.09% |
| 2019-12-31 | -8.54% |
| 2019-09-30 | -0.93% |
| 2019-06-30 | -3.88% |
| 2019-03-31 | -12.89% |
| 2018-12-31 | -7.90% |
| 2018-09-30 | -2.50% |
| 2018-06-30 | -9.29% |
| 2018-03-31 | -30.71% |
| 2017-12-31 | -30.37% |
| 2017-09-30 | -0.81% |
| 2017-06-30 | -0.70% |
| 2017-03-31 | -3.47% |
| 2016-12-31 | -29.22% |
| 2016-09-30 | -0.24% |
| 2016-06-30 | -4.29% |
| 2016-03-31 | -12.80% |
| 2015-03-31 | -22.96% |
